HGG clinical trials at UCSF

1 research study open to eligible people

HGG stands for high-grade glioma, a type of fast-growing brain tumor. UCSF is testing a drug called FORE8394 on patients with certain BRAF gene changes to see if it works well and is safe. These trials aim to offer new insights into treating complex brain cancers.

Showing trials for

  • FORE8394 in Participants With Cancer Harboring BRAF Alterations

    open to eligible people ages 10 years and up

    The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.

    San Francisco, California and other locations

Last updated: